

- 13 Masson, P. *et al.* (2001) Identification and characterization of a *Drosophila* nuclear proteasome regulator. A homolog of human 11 S REG γ (PA28 γ). *J. Biol. Chem.* 276, 1383–1390
- 14 Khan, S. *et al.* (2001) Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. *J. Immunol.* 167, 6859–6868
- 15 Watts, C. (2004) The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. *Nat. Immunol.* 5, 685–692
- 16 Yewdell, J.W. *et al.* (2003) Making sense of mass destruction: quantitating MHC class I antigen presentation. *Nat. Rev. Immunol.* 3, 952–961
- 17 Rechsteiner, M. *et al.* (2000) The proteasome activator 11 S REG (PA28) and class I antigen presentation. *Biochem. J.* 345, 1–15
- 18 Preckel, T. *et al.* (1999) Impaired immunoproteasome assembly and immune responses in PA28 $^{-/-}$ mice. *Science* 286, 2162–2165
- 19 Murata, S. *et al.* (2001) Immunoproteasome assembly and antigen presentation in mice lacking both PA28 α and PA28 β . *EMBO J.* 20, 5898–5907
- 20 Schwarz, K. *et al.* (2000) The proteasome regulator PA28 α/β can enhance antigen presentation without affecting 20S proteasome subunit composition. *Eur. J. Immunol.* 30, 3672–3679
- 21 Li, J. *et al.* (2001) Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. *Int. Immunol.* 13, 1515–1523
- 22 Yamano, T. *et al.* (2002) Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. *J. Exp. Med.* 196, 185–196
- 23 Kisselev, A.F. *et al.* (1999) The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. *J. Biol. Chem.* 274, 3363–3371
- 24 Cascio, P. *et al.* (2002) Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. *EMBO J.* 21, 2636–2645
- 25 Ordway, G.A. *et al.* (2000) Chronic contractile activity upregulates the proteasome system in rabbit skeletal muscle. *J. Appl. Physiol.* 88, 1134–1141
- 26 Fuertes, G. *et al.* (2003) Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. *Biochem. J.* 375, 75–86
- 27 Gromov, P. *et al.* (2003) Protein profiling of the human epidermis from the elderly reveals up-regulation of a signature of interferon- γ -induced polypeptides that includes manganese-superoxide dismutase and the p85 β subunit of phosphatidylinositol 3-kinase. *Mol. Cell. Proteomics* 2, 70–84
- 28 Minami, Y. *et al.* (2000) A critical role for the proteasome activator PA28 in the Hsp90-dependent protein refolding. *J. Biol. Chem.* 275, 9055–9061
- 29 Murata, S. *et al.* (1999) Growth retardation in mice lacking the proteasome activator PA28 γ . *J. Biol. Chem.* 274, 38211–38215
- 30 Barton, L.F. *et al.* (2004) Immune defects in 28-kDa proteasome activator γ -deficient mice. *J. Immunol.* 172, 3948–3954
- 31 Masson, P. *et al.* (2003) *Drosophila* proteasome regulator REG γ : transcriptional activation by DNA replication-related factor DREF and evidence for a role in cell cycle progression. *J. Mol. Biol.* 327, 1001–1012
- 32 Nikaido, T. *et al.* (1989) Loss in transformed cells of cell cycle regulation of expression of a nuclear protein recognized by SLE patient antisera. *Exp. Cell Res.* 182, 284–289
- 33 Hagemann, C. *et al.* (2003) MEKK3 interacts with the PA28 γ regulatory subunit of the proteasome. *Biochem. J.* 373, 71–79
- 34 Davis, R.J. (2000) Signal transduction by the JNK group of MAP kinases. *Cell* 103, 239–252
- 35 Imai, Y. *et al.* (1999) The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. *Nature* 398, 777–785
- 36 Yang, X. *et al.* (1997) Daxx, a novel Fas-binding protein that activates JNK and apoptosis. *Cell* 89, 1067–1076
- 37 Chen, L.Y. and Chen, J.D. (2003) Daxx silencing sensitizes cells to multiple apoptotic pathways. *Mol. Cell. Biol.* 23, 7108–7121
- 38 Bai, D. *et al.* (2003) RanBPM is a novel binding protein for p75^{NTR}. *Biochem. Biophys. Res. Commun.* 309, 552–557
- 39 Liu, B. and Shuai, K. (2001) Induction of apoptosis by protein inhibitor of activated Stat1 through c-Jun NH2-terminal kinase activation. *J. Biol. Chem.* 276, 36624–36631
- 40 Okamura, T. *et al.* (2003) Abnormally high expression of proteasome activator- γ in thyroid neoplasm. *J. Clin. Endocrinol. Metab.* 88, 1374–1383
- 41 Lipford, J.R. and Deshaies, R.J. (2003) Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. *Nat. Cell Biol.* 5, 845–850
- 42 Obradovic, D. *et al.* (2004) DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells – toward a basis for the opposite actions elicited by two nuclear receptors? *Mol. Pharmacol.* 65, 761–769
- 43 Moriishi, K. *et al.* (2003) Proteasome activator PA28 γ -dependent nuclear retention and degradation of hepatitis C virus core protein. *J. Virol.* 77, 10237–10249
- 44 Aouida, M. *et al.* (2004) A genome-wide screen in *Saccharomyces cerevisiae* reveals altered transport as a mechanism of resistance to the anticancer drug bleomycin. *Cancer Res.* 64, 1102–1109
- 45 Fehlker, M. *et al.* (2003) Blm3 is part of nascent proteasomes and is involved in a late stage of nuclear proteasome assembly. *EMBO Rep.* 4, 959–963
- 46 Lecker, S.H. *et al.* (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. *FASEB J.* 18, 39–51
- 47 Adams, J. (2004) The proteasome: a suitable antineoplastic target. *Nat. Rev. Cancer* 4, 349–360
- 48 Goasduff, T. and Cederbaum, A.I. (2000) CYP2E1 degradation by *in vitro* reconstituted systems: role of the molecular chaperone hsp90. *Arch. Biochem. Biophys.* 379, 321–330
- 49 Lu, X. *et al.* (2001) Heat shock protein-90 and the catalytic activities of the 20 S proteasome (multicatalytic proteinase complex). *Arch. Biochem. Biophys.* 387, 163–171
- 50 McCutchen-Maloney, S.L. *et al.* (2000) cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. *J. Biol. Chem.* 275, 18557–18565
- 51 Zaiss, D.M. *et al.* (2002) PI31 is a modulator of proteasome formation and antigen processing. *Proc. Natl. Acad. Sci. U. S. A.* 99, 14344–14349
- 52 Zaiss, D.M. *et al.* (1999) The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. *FEBS Lett.* 457, 333–338
- 53 Gallo, R.L. *et al.* (1994) Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. *Proc. Natl. Acad. Sci. U. S. A.* 91, 11035–11039
- 54 Gao, Y. *et al.* (2000) Inhibition of ubiquitin-proteasome pathway-mediated I κ B α degradation by a naturally occurring antibacterial peptide. *J. Clin. Invest.* 106, 439–448
- 55 Li, J. *et al.* (2000) PR39, a peptide regulator of angiogenesis. *Nat. Med.* 6, 49–55
- 56 Gaczynska, M. *et al.* (2003) Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. *Biochemistry* 42, 8663–8670
- 57 Nelbock, P. *et al.* (1990) A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. *Science* 248, 1650–1653
- 58 Seeger, M. *et al.* (1997) HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. *J. Biol. Chem.* 272, 8145–8148
- 59 Huang, X. *et al.* (2002) The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit α is crucial for their effects on proteasome function including antigen processing. *J. Mol. Biol.* 323, 771–782
- 60 Apcher, G.S. *et al.* (2003) Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal α and β subunits. *FEBS Lett.* 553, 200–204
- 61 Hu, Z. *et al.* (1999) Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. *J. Virol.* 73, 7231–7240
- 62 Huang, J. *et al.* (1996) Proteasome complex as a potential cellular target of hepatitis B virus X protein. *J. Virol.* 70, 5582–5591
- 63 Stohwasser, R. *et al.* (2003) Hepatitis B virus HBx peptide 116–138 and proteasome activator PA28 compete for binding to the proteasome α /MC6 subunit. *Biol. Chem.* 384, 39–49
- 64 Unno, M. *et al.* (2002) The structure of the mammalian 20S proteasome at 2.75 Å resolution. *Structure* 10, 609–618